Allogene Therapeutics (NASDAQ:ALLO) SVP Earl Martin Douglas Sells 22,900 Shares

Allogene Therapeutics, Inc. (NASDAQ:ALLO) SVP Earl Martin Douglas sold 22,900 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $1.76, for a total value of $40,304.00. Following the sale, the senior vice president directly owned 564,948 shares of the company’s stock, valued at approximately $994,308.48. The trade was a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Allogene Therapeutics Stock Performance

ALLO stock traded up $0.06 during mid-day trading on Wednesday, hitting $1.80. 6,031,813 shares of the company were exchanged, compared to its average volume of 6,604,055. The firm has a market cap of $404.51 million, a P/E ratio of -1.84 and a beta of 0.60. Allogene Therapeutics, Inc. has a 1-year low of $0.86 and a 1-year high of $3.78. The firm’s 50 day simple moving average is $1.51 and its 200 day simple moving average is $1.32.

Allogene Therapeutics (NASDAQ:ALLO) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.04. On average, equities research analysts predict that Allogene Therapeutics, Inc. will post -1.28 EPS for the current fiscal year.

Institutional Trading of Allogene Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ALLO. AQR Capital Management LLC acquired a new position in shares of Allogene Therapeutics during the 1st quarter worth about $85,000. Goldman Sachs Group Inc. grew its holdings in Allogene Therapeutics by 177.9% during the first quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company’s stock worth $8,547,000 after purchasing an additional 3,747,397 shares during the period. Jane Street Group LLC increased its position in Allogene Therapeutics by 578.7% during the first quarter. Jane Street Group LLC now owns 1,116,681 shares of the company’s stock worth $1,630,000 after buying an additional 952,158 shares during the last quarter. Vanguard Personalized Indexing Management LLC raised its stake in Allogene Therapeutics by 183.5% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 71,688 shares of the company’s stock valued at $81,000 after buying an additional 46,398 shares during the period. Finally, R Squared Ltd acquired a new stake in shares of Allogene Therapeutics in the second quarter valued at approximately $37,000. 83.63% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on ALLO shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Allogene Therapeutics in a research report on Wednesday, October 8th. Citizens Jmp raised Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price target for the company in a research report on Friday, January 9th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of Allogene Therapeutics in a report on Friday, October 10th. Wall Street Zen raised shares of Allogene Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, November 28th. Finally, Citigroup raised shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Friday, January 9th. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.40.

Allogene Therapeutics Company Profile

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.